Sun Pharma’s application for a bioequivalence and phase III trial waiver for its Sitagliptin, Glimepiride, and Metformin fixed-dose combination has been rejected by the CDSCO.

Sun Pharma’s application for a bioequivalence and phase III trial waiver for its Sitagliptin, Glimepiride, and Metformin fixed-dose combination has been rejected by the CDSCO.

by | Sep 7, 2025 | Pharma, Sun Pharma

Sun Pharmaceutical Industries, a prominent pharmaceutical company, has faced a setback in its attempt to secure approval from the Central Drugs Standard Control Organisation (CDSCO) for a bioequivalence (BE) study and Phase III clinical trial waiver for its fixed-dose...
Sun Pharma’s application for a bioequivalence and phase III trial waiver for its Sitagliptin, Glimepiride, and Metformin fixed-dose combination has been rejected by the CDSCO.

Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.

by | Aug 26, 2025 | Aurobindo Pharma, Cipla, Lupin, Pharma, Sun Pharma

The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce...